Business
InMed Announces Appointment of Joshua Blacher as Chief Business Officer
InMed Announces Appointment of Joshua Blacher as Chief Business Officer Canada New...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Announces Appointment of Joshua Blacher as Chief Business Officer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, April 11, 2018\n\n\n\nTSX: INOTCQB: IMLFF \n\n\n\nVANCOUVER, April 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the appointment of Joshua Blacher as Chief Business Officer.  In this capacity, Mr. Blacher will be focusing on raising the Company's visibility in the broader capital markets community, especially in the United States, as well as executing strategic finance initiatives and business development.\n\n\n \n \n\n \nMr. Blacher joins InMed with twenty years of leadership experience in senior positions in the healthcare and capital markets sectors in the United States.  Before joining InMed, Mr. Blacher served as Chief Financial Officer at Therapix Biosciences (NASDAQ: TRPX) and Galmed Pharmaceuticals (NASDAQ: GLMD), where he focused on strategic finance, business development, and managing relations with the investment community.  Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers.  Mr. Blacher holds an MBA in Finance from Columbia Business School.\n\nEric A. Adams, InMed's President and CEO, commented, \"Josh brings his many years of experience in successfully helping to build a larger vision for high-growth biopharmaceutical companies, executing investor-focused awareness, and putting together strategic collaborations.\"  Mr. Adams continued, \"Adding Josh's unique skill set to our executive team is very timely to InMed, as we have now secured the capital and human talent to drive the Company into its next stage of strategic growth and execution of our focused business model.\"\n\n\"InMed's valuable platf...